Revvity, Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 491 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Name change on a long-lived CIK: CIK 0000031791 was named EG&G Inc from 1994-03-17 to 1999-07-26, then PerkinElmer Inc from 1999-11-05 to 2023-04-14, then renamed Revvity, Inc. (confirmed via SEC EDGAR submissions API formerNames field). Company legal name written as the current legal name 'Revvity, Inc.' per the project's rule.
• Every 13F row in this register was matched on CUSIP 714046109, confirmed fresh from the information tables themselves (issuer name filed variously as 'REVVITY INC'), never on an issuer-name text search, to avoid missing rows still filed under a legacy PerkinElmer-era name string or sweeping in an unrelated similarly-named issuer.
• Holdings side: searched Revvity's newest 10-Q (period ended 5 Jul 2026, filed 11 Aug 2026, the freshest filing on record, fresher than the FY2025 10-K filed 24 Feb 2026 which covers fiscal year ended 28 Dec 2025) for 'equity method', 'equity investment', 'non-marketable', 'retained interest', 'unconsolidated', 'joint venture', 'cost method', 'investments in affiliates', 'variable interest entity': zero hits on all terms. Repeated the same search against the full FY2025 10-K: zero hits on all the same terms plus 'minority interest', 'strategic investment', 'non-controlling'. Also checked the FY2025 10-K's Exhibit 21 subsidiaries list, which states 'Except as noted, all voting securities of the listed subsidiaries are 100% beneficially owned by the Ultimate Parent or a subsidiary thereof' and lists only wholly owned subsidiaries with no ownership-percentage column and no partial-ownership entities flagged; a genuine negative, not evidence of looking in the wrong place.
• The 2023 divestiture (sale of the Applied, Food and Enterprise Services businesses, formerly reported under the Discovery & Analytical Solutions segment) was confirmed via the FY2025 10-K Note 3 (Discontinued Operations) to be an all-cash transaction for approximately $2.27 billion in cash proceeds before transaction costs, with no retained equity interest in the divested business. The only ongoing consideration is a contractual 'Brand Fee' of up to an additional $75.0 million payable in installments tied to Revvity ceasing use of the PerkinElmer trademark and transferring it to the buyer (a licensing/royalty arrangement, not an equity stake); the company received $56.2 million of that fee across fiscal 2024 and 2025. Conclusion: this is a checked negative. Revvity holds no material equity stake, listed or private, arising from this divestiture or disclosed elsewhere in the newest 10-K/10-Q, so the holdings array is empty by design.
• Company shares_outstanding 111,586,401 taken from the cover page of the Q2 2026 10-Q (period ended 5 Jul 2026, filed 11 Aug 2026), 'As of August 6, 2026, there were outstanding 111,586,401 shares of common stock, $1 par value per share.' Single class of common stock; no dual-class structure.
• Market cap $13,328,995,599 computed as 111,586,401 shares times the NYSE closing price of $119.45 on 19 Aug 2026 (Nasdaq quote API, secondaryData field, marked 'Closed at Aug 19, 2026 4:00 PM ET').
• Vanguard family case: parent CIK 0000102909 filed Form 13F-NT (a notice carrying no holdings) for Q2 2026, filed 13 Aug 2026, so per the project's rule the 7 successor entities are summed as the position (see the Vanguard row's method_note for the full entity/CIK/share breakdown). An 8th entity sometimes seen elsewhere, Vanguard National Trust Co CIK 0001984256, was checked independently and confirmed to hold zero Revvity shares in its own Q2 2026 13F-HR.
• Capital Group family checked per the project's standing instruction, despite being entirely absent from data/registers/RVTY.json: Capital World Investors CIK 0001422849 and Capital International Investors CIK 0001562230 each hold zero Revvity shares in their Q2 2026 13F-HR filings (CUSIP 714046109 search returned no match in either); Capital Research Global Investors CIK 0001422848 holds a negligible 12,294 shares ($1,367,830), about 0.01% of the company. Unlike the L3Harris precedent in the project's own documentation, the register snapshot's omission of Capital Group is accurate here: the family is genuinely immaterial for Revvity, so no Capital Group row is included.
• data/registers/RVTY.json (31 Mar 2026 snapshot) was used only to identify WHO to check (entity names and CIKs for the Vanguard sweep), never for share figures; every figure in this register was independently re-fetched from each holder's own Q2 2026 (period 2026-06-30) 13F-HR information table.
• Self-gate computed on this final file per the project's chart arithmetic (raw shares summed; the insider aggregate row has no rolls_up_into members, so it counts at full value like every other row): 13 register rows, total shares 81,734,243 (80,788,248 across the 12 institutional/index rows plus 945,995 in the insider aggregate row), 81,734,243 / 111,586,401 = 73.25% of the company. This is above the 55% flag threshold in the brief, so it was independently corroborated three ways: (1) data/registers/RVTY.json reports total_shares_reported 115,469,759 across 491 filers as of 31 Mar 2026, i.e. roughly 103% of the 111,586,401 current shares outstanding, meaning Revvity is close to wholly institutionally held and a concentrated top-12-plus-insiders register is the expected shape, not an anomaly; (2) every one of the 12 institutional rows was read from a DISTINCT filer family's own fresh Q2 2026 13F-HR (T. Rowe Investment Management and T. Rowe Associates are confirmed separate SEC registrants, and the Vanguard row is a 7-entity family sum with no overlap against any other row); (3) back-solved the shares_outstanding denominator from two of Revvity's own 2026 proxy 5%-owner rows: T. Rowe Price Investment Management 22,447,103 shares at 20.1% implies a denominator of about 111,678,124, and The Vanguard Group 14,177,103 shares at 12.7% implies about 111,631,520; both land within about 0.1% of the actual 111,586,401 cover-page figure, confirming the denominator independently.
• Implied-price check run on every row: all 12 institutional/index rows and the T. Rowe values-in-thousands correction converge on approximately $111.05 to $111.26 per share as of 30 Jun 2026, except Janus Henderson Group plc, whose entire Q2 2026 13F-HR filing (all 5 lines) prices Revvity at approximately $87.61/sh; kept as filed and flagged in that row's method_note rather than corrected, since no round unit-conversion factor (1000x, 100x, 10x) reconciles it and the price is independently plausible against Revvity's roughly $81 to $118 52-week range.
• Institutional 13F share counts declined across the board from the DEF 14A's cited 13G/A figures (dated variously around 31 Dec 2025 or the 17 Feb 2026 record date) to the fresher Q2 2026 (30 Jun 2026) 13F-HR figures used in this register for T. Rowe Price Investment Management, T. Rowe Price Associates, Vanguard and BlackRock, while EdgePoint was roughly flat and Janus Henderson rose; each row's method_note states both figures and which was used, per the project's rule to prefer the fresh 13F.
• All executive officers and directors as a group (14 persons) held 945,995 shares, 0.85% of the company, per the 2026 DEF 14A; no individual director or named executive officer exceeds 1%, so no separate insider member rows were added and this aggregate row is not linked to any rolls_up_into members.
• Coordinator verification of the 73.25 per cent self-gate, above the project's 55 per cent line. Corroborated per holder against this project's own 13F-derived snapshot at data/registers/RVTY.json, built from 491 filers at 31 Mar 2026 and independent of the filings read here: Vanguard 13,161,308 there against 13,072,887 here, EdgePoint 8,800,863 against 8,544,479, BlackRock 7,250,376 against 7,658,369, State Street 4,310,313 against 4,342,739, and the snapshot's single combined T. Rowe entry at 22,198,422 against the two separate registrant rows here summing to 23,792,027. The snapshot reports 115,469,759 shares against 111,586,401 outstanding, approximately 103.5 per cent, which is above the whole company and is the documented 13F over-reporting effect; it confirms Revvity is effectively wholly institutionally held, so a top-thirteen at 73.25 per cent is consistent rather than anomalous. One row was checked specifically because it looked suspicious: Janus Henderson's 8,348,127 shares match the Q1 snapshot to the exact share, which is the signature of copying a snapshot figure rather than reading a filing. It is not: the row is sourced to Janus Henderson's own Q2 2026 13F-HR, CIK 0001274173, summed across 5 lines, and the identical count simply means the holder did not trade the position between quarters. A NEW FILER-LEVEL PRICING ANOMALY is recorded on that same row and is worth carrying alongside the existing APG question: all five of Janus Henderson's lines price Revvity at about $87.61 per share against about $111.26 implied by every other Q2 2026 filer checked, a gap of roughly 21 per cent. That is neither the roughly 1000x values-in-thousands signature nor the roughly 12 per cent APG pattern, so it is a third and distinct case. It was correctly kept AS FILED and flagged rather than adjusted, because a value that merely looks wrong is not evidence of which convention produced it.